5个糖化血红蛋白检测系统对Hb NewYork合并β地中海贫血标本异常结果预警能力比较
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

广东省科技计划项目(20138021800112);中山市卫生局课题(2014J040);中山市科技局重大项目(2015B1002)。


Comparison of early-warning ability of five different detection systems for erroneous glycosylated hemoglobin results from compand heterozygotes of hemoglobulin NewYork acompainying β-thalassemia
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    摘要:目的:通过分析不同糖化血红蛋白检测系统检测Hb NewYork合并β地中海贫血(简称“地贫”,双重杂合子)标本的结果,观察不同系统对该双重杂合子的预警能力。 方法:收集40例HbA1c不同分布范围的无血红蛋白病的标本,以通过NGSP Ⅰ级检测实验室认证的VariantⅡ(VⅡ)糖化血红蛋白检测系统作为参考系统,VariantⅡTurbo2.0(VⅡT)、Capillary 2 Flex Piercing(C2FP)、Primus Ultra2(Ultra2)、Modular PPI 800(PPI)系统为比对系统检测标本,以判断比对系统与参考系统结果的一致性。收集2例异常血红蛋白Hb NewYork合并β地贫血患者全血及血清标本,用5个糖化血红蛋白检测系统检测2例标本HbA1c。用毛细管电泳法对2例标本进行血红蛋白电泳分析,用GAPPCR、原位杂交及双脱氧链终止法检测血红蛋白基因。 结果:对于无血红蛋白病患者全血标本,其他4个检测系统与VariantⅡ系统的一致性良好。2例患者的血红蛋白基因型分别为aa/aa,βIVS2654/βNewYork;aa/aa,β4142/βNewYork;HbA含量均为0%,Hb NewYork含量分别为93.5%和94.0%;VⅡ的HbA1c检测结果分别为4.3%(23 mmol/mol)和4.5%(26 mmol/mol);VⅡT2.0的检测结果分别为4.5%(26 mmol/mol)和4.6%(27 mmol/mol);C2FP未检出HbA1c;Ultra2的结果分别为4.1%(21 mmol/mol)和4.3%(23 mmol/mol);PPI的检测结果为4.2%(22 mmol/mol)和4.8%(29 mmol/mol)。检测系统无异常报警。 结论:5个检测系统对Hb NewYork双重杂合子的检测预警能力不同,Hb NewYork双重杂合子标本理论上不含HbA1c,VⅡ、VⅡT、Ultra2、PPI检测系统报告了HbA1c结果,对该标本无预警能力,而C2FP系统未报告检测结果,对此标本有预警能力。

    Abstract:

    Abstract: Objective:To analyze the HbA1c results of double heterozygotes of hemoglobin(Hb)NewYork and β-thalassemia detected by five different HbA1c detection systems, and compare the early-warning abilities of erroneous glycosylated hemoglobin results for Hb NewYork and β-thalassemia heterozygotes. Methods:Peripheral blood samples from 40 patients without hemoglobinopathies with different range of HbA1c levels were collected to evaluate the consistency of the detected results. Variant Ⅱ system was used as the reference system which successfully completed NGSP Level Ⅰ laboratory certification. Variant Ⅱ Turbo 2.0(VⅡT), Capillary 2 Flex Piercing(2FP), Primus Ultra2(Ultra2)and Roche Modular PPI(PPI)800 were used as the comparative systems. The HbA1c in 2 sera from the patients with compand heterozygotes of Hb NewYork was detected by the above systems. Hemoglobin electrophoresis was performed. Gentypes of αand β-globin genes were analyzed by GAPPCR, hybridization and dideoxy chain termination method. Results:The HbA1c values in nonhemoglobinophthy samples obtained using VⅡT 2.0, Ultra2, C2FP and PPI systems were well correlated with that of VⅡ system. The hemoglobin genotypes of the two cases of compand heterozygotes were aa/aa, βIVS2654/βNewYork and aa/aa, β4142/βNewYork, respectively. The proportions of HbA were all 0 while the proportions of Hb NewYork were 93.5% and 94.0% respectively. The HbA1c results of the two cases detected were 4.3%(23 mmol/mol)and 4.5%(26 mmol/mol)by VⅡ, 4.5%(26 mmol/mol)and 4.6%(27 mmol/mol)by VⅡT 2.0, no values and no values by C2FP, 4.1%(21 mmol/mol)and 4.3%(23 mmol/mol)by Ultra2 and 4.2%(22 mmol/mol)and 4.8%(29 mmol/mol)by PPI systems, respectively. All the systems did not send warning for abnormal signs in profiles and results. Conclusion:The five systems presented different earlywarning ability for the double heterozygotes of Hb NewYork and β-thalassemia. The compand heterozygotes should theoretically not contain HbA1c, but the systems VⅡ, VⅡT, Ultra2 and PPI showed detectable results of HbA1c indicating all the four systems were not able to provide with earlywarning. C2FP system did not report HbA1c result so it exhibited earlywarning ability for the double heterozygote.

    参考文献
    相似文献
    引证文献
引用本文

索明环,温冬梅,王伟佳,张德才,胡婷,王霞.5个糖化血红蛋白检测系统对Hb NewYork合并β地中海贫血标本异常结果预警能力比较[J].临床检验杂志,2017,(9):649-653

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2017-03-20
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2017-10-10
  • 出版日期:
文章二维码
您是第位访问者  苏ICP备13058113号-3
苏公网安备32010202012004号
主管单位:江苏省医学会  出版单位:临床检验杂志
单位地址:江苏省南京市中央路42号  邮编:210008
电话:025-83620683 E-MAIL:lcjyzz@163.com
技术支持:北京勤云科技发展有限公司